Eli Lilly and Company (LLY) Stock

About Eli Lilly and Company

Eli Lilly and Company is a prominent global pharmaceutical firm dedicated to the research, development, and commercialization of human medicines across the world. Its therapeutic offerings include a comprehensive suite of diabetes medications. This encompasses various insulin formulations like Basaglar, the Humalog family (e.g., Mix 75/25, U-100, U-200, Mix 50/50), insulin lispro products (including protamine and mix 75/25), and the Humulin line (e.g., 70/30, N, R, U-500). Furthermore, Eli Lilly provides specialized treatments for type 2 diabetes, such as Jardiance, Trajenta, and Trulicity. In oncology, Eli Lilly offers a robust portfolio targeting various cancers. These include Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza, indicated for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal and various head and neck cancers; Retevmo, used in metastatic NSCLC, medullary thyroid, and other thyroid cancers; Tyvyt for relapsed or refractory classic Hodgkin's lymphoma and non-squamous NSCLC; and Verzenio, prescribed for HR+, HER2- metastatic breast cancer, node-positive, and early breast cancer. For autoimmune and inflammatory conditions, the company markets Olumiant for rheumatoid arthritis, and Taltz, which addresses plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Addressing neurological and pain management needs, Eli Lilly provides Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain. Emgality is available for migraine prevention and episodic cluster headaches, while Zyprexa treats schizophrenia, bipolar I disorder, and aids in bipolar maintenance. Other significant products include Bamlanivimab and etesevimab, along with Bebtelovimab, both developed for COVID-19. Cialis is offered for erectile dysfunction and benign prostatic hyperplasia, and Forteo is available for osteoporosis. Eli Lilly actively engages in strategic collaborations with numerous partners, including Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Established in 1876, Eli Lilly and Company maintains its corporate headquarters in Indianapolis, Indiana.

Eli Lilly and Company is led by CEO David A. Ricks, employs 47,000 people, headquartered in Indianapolis, US, publicly traded since 1972.

Eli Lilly and Company (LLY) stock trades at $1185.71 with a market capitalization of $1.12T. The stock is valued at a price-to-earnings (P/E) ratio of 34.66, price-to-book of 27.92, price-to-sales of 14.63. Over the past 52 weeks the stock has ranged between $623.78 and $1245.88, and currently trades 4.8% below its 52-week high. It pays a dividend yielding 0.58%.

On profitability, Eli Lilly and Company generates a return on equity (ROE) of 1.07%, return on capital employed of 111.91%, an operating margin of 45.56%, a net profit margin of 34.98%.

In its most recent fiscal year, Eli Lilly and Company reported annual revenue of $65.2B, net profit of $20.6B, revenue has compounded at 21.6% a year over the last five years, profit at 27.2% a year. Profit growing faster than revenue points to expanding margins.

The balance sheet shows a debt-to-equity ratio of 1.39, a current ratio of 1.58, total assets of $112.5B, $7.2B in cash and equivalents.

LLY has an average daily trading volume of 3,160,000 shares, a beta of 0.52 (less volatile than the overall market).

Official website: www.lilly.com